Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.

Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating biaryl P4 groups, producing highly potent inhibitors with encouraging oral pharmacokinetic profiles and significant but sub-optimal anticoagulant activities.

[1]  Stefan Senger,et al.  Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. , 2007, Journal of medicinal chemistry.

[2]  A. Spyropoulos.  Investigational treatments of venous thromboembolism , 2007, Expert opinion on investigational drugs.

[3]  T. Williams,et al.  Efficient synthesis of 1-heterocyclic-3-aminopyrrolidinones , 2000 .

[4]  Stefan Senger,et al.  Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[5]  M. Abraham,et al.  Rapid method for the estimation of octanol/water partition coefficient (log P(oct)) from gradient RP-HPLC retention and a hydrogen bond acidity term (zetaalpha(2)(H)). , 2001, Current medicinal chemistry.

[6]  P. Lam,et al.  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.

[7]  L. Sorbera,et al.  Dabigatran/dabigatran etexilate : Pevention of DVT prevention of ischemic stroke thrombin inhibitor , 2005 .

[8]  A. Kalgutkar,et al.  Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. , 2007, Current drug metabolism.

[9]  E. Saiah,et al.  Small molecule coagulation cascade inhibitors in the clinic. , 2005, Current topics in medicinal chemistry.

[10]  A. Spyropoulos.  Brave new world: the current and future use of novel anticoagulants. , 2008, Thrombosis research.

[11]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[12]  J. Weitz,et al.  Beyond heparin and warfarin: the new generation of anticoagulants , 2007, Expert opinion on investigational drugs.

[13]  Liang-Shang Gan,et al.  Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR. , 2002, Chemical research in toxicology.

[14]  P. Lam,et al.  Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Q. Ma.  Development of oral anticoagulants. , 2007, British journal of clinical pharmacology.

[16]  Mostofa A Hena,et al.  The discovery of glycine and related amino acid-based factor Xa inhibitors. , 2006, Bioorganic & medicinal chemistry.

[17]  Corwin Hansch,et al.  A survey of Hammett substituent constants and resonance and field parameters , 1991 .

[18]  Stefan Senger,et al.  Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. , 2006, Bioorganic & medicinal chemistry letters.

[19]  Christopher R. Emerson,et al.  Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor , 2009, Pharmacotherapy.

[20]  A. Mutlib,et al.  P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)- [1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogues to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes. , 2002, Chemical research in toxicology.

[21]  Leadley Rj,et al.  Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. , 2003 .

[22]  P. Zhou,et al.  Antithrombotic Potential of GW813893: A Novel, Orally Active, Active-site Directed Factor Xa Inhibitor , 2008, Journal of cardiovascular pharmacology.

[23]  R. Mohanty,et al.  Asymmetric Reductive Amination: Convenient Access to Enantioenriched Alkyl‐Alkyl or Aryl‐Alkyl Substituted α‐Chiral Primary Amines , 2006 .

[24]  M. Abraham,et al.  Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. , 2003, Journal of pharmaceutical sciences.

[25]  J. Weitz,et al.  Dabigatran etexilate for prevention of venous thromboembolism , 2008, Thrombosis and Haemostasis.

[26]  Stefan Senger,et al.  Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. , 2008, Bioorganic & medicinal chemistry letters.

[27]  Ingemar Nilsson,et al.  A new oral anticoagulant: the 50-year challenge , 2004, Nature Reviews Drug Discovery.

[28]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[29]  B. Eriksson,et al.  Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development , 2009, Clinical pharmacokinetics.

[30]  J. Alexander,et al.  Inhibition of Factor Xa , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[31]  G. Escolar,et al.  Rivaroxaban : Factor Xa inhibitor prop INN anticoagulant , 2006 .

[32]  Yong-Jin Wu,et al.  Synthesis of fluorinated 1-(3-morpholin-4-yl-phenyl)-ethylamines. , 2003, Bioorganic & medicinal chemistry letters.